EVALUATING A NOVEL HOST-IMMUNE BASED ASSAY FOR DISTINGUISHING BACTERIAL FROM VARIOUS VIRAL INFECTIONS



IN FEBRILE CHILDREN




Eran Eden^a, Isaac Srugo^{b,c}, Asi Cohen^a, Roy Navon^a, Olga Boico^a, Tanya Gottlieb^a, Ellen Bamberger^{a,b,c}, Meital Paz^a, Liat Etshtein^a, Liran Shani^a, Michal Stein^d, Adi Klein^d and Kfir Oved^a

^aMeMed Diagnostics, Tirat Carmel, Israel, ^bBnai-Zion Medical Center, Haifa, ^cTechnion – Israel Institute of Technology, Haifa, Israel, ^dHillel Yaffe Medical Center, Hadera, Israel.


Background

1. A novel host-immune signature



Oved et al. PLOS ONE 2015


2. A new IVD assay for distinguishing between bacterial and viral



4. Study goal


To evaluate the assay's ability to assign correct infection classification (viral or bacterial) in children infected with ten different types of viral strains as well as in bacterially infected children


3. Assay validated in several clinical studies



'Curiosity' study - Oved et al. *PLOS ONE* 2015; Eden et al. *Journal of Infection* 2016. 'Opportunity' study – van-Houten et al *Lancet Infectious Diseases* 2016.

Design and Results





- ImmunoXpert[™] correctly classified 90% of bacterial cases and 91% of viral cases, when compared to the expert panel diagnoses (13% of patients had an equivocal response).
- Assay classified all coronavirus, bocavirus, human metapneumovirus, and enterovirus cases correctly.
- In the case of adenovirus, which is known to trigger a bacterial-like inflammatory host response, the assay correctly classified 83% of the patients. In comparison, CRP (cut-off: 40 mg/l) correctly classified only 42% of adenovirus infections.
- The assay may aid clinicians in determining infection etiology in febrile children. Importantly, it may assist in distinguishing between adenovirus and bacterial infections, which can be associated with similar clinical presentation.